Results of multiple myeloma treatment with bortezomib
Bortezomib efficacy in I, II and subsequent therapy lines was studied at 51 multiple myeloma (MM) patients in Novosibirsk Hematological Center. The median of age was 66 years (39—87); patients have received from 4 to 12 therapy courses, totally — 363 courses. Total efficacy of the I line therapy was...
Saved in:
| Main Authors: | T. I. Pospelova, N. V. Skvortzova, I. N. Nechunaeva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/738 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01) -
Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01) -
Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients
by: Eva Plakoula, et al.
Published: (2025-01-01) -
Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)